Virendar Kaushik is the PCSK9 Pathway Project lead and group leader of Biochemistry/Biophysics within the Therapeutics Projects Group at the Broad Institute. The PCSK9 project goal is to develop a safe, small molecule PCSK9 inhibitor that will decrease plasma LDL cholesterol, thus reducing the risk of myocardial infarction (heart attack) in humans. The Biochemistry/Biophysics lab focus is on assay and process design to develop and implement best practices for identifying, validating, and progressing small molecules as therapeutic agents.
Before coming to the Broad, Kaushik was an investigator within the Cardiovascular and Metabolic Disease Area at the Novartis Institutes for Biomedical Research, Inc. (NIBRI). His focus was on developing and executing the biochemistry strategy for therapeutics projects, and leading cross-functional pre-clinical discovery project teams. Prior to NIBRI, Kaushik did research into metabolic diseases and obesity at
Kaushik received his undergraduate (biology) and masters (physiology) degrees from Boston University. He received his Ph.D. in nutritional biochemistry from Tufts University.Last updated date: May 2013